Vanguard Group’s Actinium Pharmaceuticals ATNM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $1.93M | Buy |
1,421,038
+36,495
| +3% | +$53.2K | ﹤0.01% | 3566 |
|
|
2025
Q3 | $2.22M | Buy |
1,384,543
+12,703
| +0.9% | +$20.7K | ﹤0.01% | 3548 |
|
|
2025
Q2 | $1.92M | Sell |
1,371,840
-199,924
| -13% | -$299K | ﹤0.01% | 3544 |
|
|
2025
Q1 | $2.53M | Sell |
1,571,764
-45,608
| -3% | -$57.9K | ﹤0.01% | 3414 |
|
|
2024
Q4 | $2.04M | Sell |
1,617,372
-7,628
| -0.5% | -$11.8K | ﹤0.01% | 3561 |
|
|
2024
Q3 | $3.06M | Buy |
1,625,000
+145,790
| +10% | +$576K | ﹤0.01% | 3434 |
|
|
2024
Q2 | $10.9M | Buy |
1,479,210
+32,884
| +2% | +$271K | ﹤0.01% | 2862 |
|
|
2024
Q1 | $11.3M | Buy |
1,446,326
+82,113
| +6% | +$528K | ﹤0.01% | 2888 |
|
|
2023
Q4 | $6.93M | Buy |
1,364,213
+22,664
| +2% | +$117K | ﹤0.01% | 3144 |
|
|
2023
Q3 | $7.94M | Buy |
1,341,549
+7,267
| +0.5% | +$48.4K | ﹤0.01% | 3019 |
|
|
2023
Q2 | $9.9M | Buy |
1,334,282
+50,382
| +4% | +$429K | ﹤0.01% | 2945 |
|
|
2023
Q1 | $12.1M | Buy |
1,283,900
+166,849
| +15% | +$1.76M | ﹤0.01% | 2834 |
|
|
2022
Q4 | $11.9M | Buy |
1,117,051
+48,104
| +5% | +$488K | ﹤0.01% | 2875 |
|
|
2022
Q3 | $7.89M | Hold |
1,068,947
| – | – | ﹤0.01% | 3078 |
|
|
2022
Q2 | $5.14M | Buy |
1,068,947
+210,110
| +24% | +$1.19M | ﹤0.01% | 3366 |
|
|
2022
Q1 | $4.39M | Sell |
858,837
-6,752
| -0.8% | -$35.6K | ﹤0.01% | 3596 |
|
|
2021
Q4 | $5.2M | Sell |
865,589
-1,142
| -0.1% | -$8.57K | ﹤0.01% | 3589 |
|
|
2021
Q3 | $7.68M | Buy |
866,731
+47,089
| +6% | +$327K | ﹤0.01% | 3399 |
|
|
2021
Q2 | $6.48M | Buy |
819,642
+247,122
| +43% | +$1.94M | ﹤0.01% | 3448 |
|
|
2021
Q1 | $4.36M | Buy |
572,520
+13,740
| +2% | +$117K | ﹤0.01% | 3600 |
|
|
2020
Q4 | $4.36M | Buy |
558,780
+54,285
| +11% | +$590K | ﹤0.01% | 3423 |
|
|
2020
Q3 | $4.89M | Buy |
504,495
+10,313
| +2% | +$114K | ﹤0.01% | 3158 |
|
|
2020
Q2 | $5.21M | Buy |
494,182
+342,537
| +226% | +$2.59M | ﹤0.01% | 3082 |
|
|
2020
Q1 | $883K | Sell |
151,645
-3,249
| -2% | -$23.1K | ﹤0.01% | 3526 |
|
|
2019
Q4 | $1.01M | Hold |
154,894
| – | – | ﹤0.01% | 3637 |
|
|
2019
Q3 | $1.07M | Buy |
154,894
+54,018
| +54% | +$376K | ﹤0.01% | 3635 |
|
|
2019
Q2 | $745K | Sell |
100,876
-51,068
| -34% | -$513K | ﹤0.01% | 3750 |
|
|
2019
Q1 | $2.19M | Buy |
151,944
+40,776
| +37% | +$651K | ﹤0.01% | 3419 |
|
|
2018
Q4 | $1.29M | Buy |
111,168
+25,310
| +29% | +$432K | ﹤0.01% | 3490 |
|
|
2018
Q3 | $1.91M | Buy |
85,858
+5,146
| +6% | +$105K | ﹤0.01% | 3549 |
|
|
2018
Q2 | $1.55M | Sell |
80,712
-2,064
| -2% | -$26.2K | ﹤0.01% | 3568 |
|
|
2018
Q1 | $907K | Sell |
82,776
-299
| -0.4% | -$5.08K | ﹤0.01% | 3666 |
|
|
2017
Q4 | $1.65M | Buy |
83,075
+11,431
| +16% | +$230K | ﹤0.01% | 3483 |
|
|
2017
Q3 | $1.24M | Buy |
71,644
+186
| +0.3% | +$4.08K | ﹤0.01% | 3536 |
|
|
2017
Q2 | $2.62M | Buy |
71,458
+4,952
| +7% | +$207K | ﹤0.01% | 3302 |
|
|
2017
Q1 | $3.01M | Buy |
66,506
+15,331
| +30% | +$588K | ﹤0.01% | 3248 |
|
|
2016
Q4 | $1.34M | Sell |
51,175
-4,548
| -8% | -$142K | ﹤0.01% | 3487 |
|
|
2016
Q3 | $2.26M | Buy |
55,723
+3,015
| +6% | +$155K | ﹤0.01% | 3339 |
|
|
2016
Q2 | $2.8M | Buy |
52,708
+8,478
| +19% | +$473K | ﹤0.01% | 3238 |
|
|
2016
Q1 | $2.64M | Buy |
44,230
+6,559
| +17% | +$414K | ﹤0.01% | 3269 |
|
|
2015
Q4 | $3.65M | Buy |
37,671
+6,043
| +19% | +$402K | ﹤0.01% | 3129 |
|
|
2015
Q3 | $1.68M | Buy |
31,628
+3,847
| +14% | +$257K | ﹤0.01% | 3452 |
|
|
2015
Q2 | $2.21M | Buy |
27,781
+1,957
| +8% | +$167K | ﹤0.01% | 3369 |
|
|
2015
Q1 | $1.91M | Buy |
25,824
+8,118
| +46% | +$966K | ﹤0.01% | 3435 |
|
|
2014
Q4 | $3.13M | Buy |
17,706
+626
| +4% | +$119K | ﹤0.01% | 3109 |
|
|
2014
Q3 | $3.43M | Buy |
17,080
+998
| +6% | +$198K | ﹤0.01% | 3033 |
|
|
2014
Q2 | $3.48M | Buy |
+16,082
| New | +$5.36M | ﹤0.01% | 3012 |
|
Other funds holding ATNM
GS
GWP
Vanguard Group's ATNM Position: Q4 2025 in Review
Vanguard Group increased its Actinium Pharmaceuticals (ATNM) stake by 2.6% in Q4 2025, buying an estimated $53.2K and bringing the position to 1,421,038 shares worth $1.93M. The position accounts for ﹤0.01% of the portfolio, ranked #3566.
Vanguard Group first reported a position in ATNM in Q2 2014 and has held it in 47 quarters since. The position peaked at $12.1M in Q1 2023. 60 funds tracked by Wall St. Rank hold ATNM as of Q4 2025.
- Vanguard Group held 1,421,038 shares of Actinium Pharmaceuticals worth $1.93M as of Q4 2025.
- Vanguard Group bought 36,495 Actinium Pharmaceuticals shares in Q4 2025, an estimated $53.2K.
- Actinium Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3566 holding.
- Vanguard Group first reported a position in Actinium Pharmaceuticals in Q2 2014 and has held it in 47 quarters since.
- Vanguard Group's Actinium Pharmaceuticals position peaked at $12.1M in Q1 2023.
- 60 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.